MassMutual Private Wealth & Trust FSB Purchases 825 Shares of Bruker Corporation $BRKR

MassMutual Private Wealth & Trust FSB increased its position in shares of Bruker Corporation (NASDAQ:BRKR) by 75.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,916 shares of the medical research company’s stock after buying an additional 825 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Bruker were worth $79,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Pinnacle Bancorp Inc. acquired a new stake in Bruker in the 1st quarter worth $29,000. Allworth Financial LP lifted its holdings in Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 745 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 347 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Bruker in the 1st quarter valued at about $42,000. 79.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BRKR. Barclays lowered their price objective on shares of Bruker from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Monday, August 4th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Wells Fargo & Company reduced their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. Citigroup cut their price target on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Finally, Bank of America dropped their price target on shares of Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Five analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $51.30.

Insider Transactions at Bruker

In related news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 27.30% of the stock is currently owned by company insiders.

Bruker Stock Down 0.3%

Shares of NASDAQ BRKR opened at $33.17 on Friday. The company has a 50 day simple moving average of $35.03 and a 200 day simple moving average of $38.40. The firm has a market cap of $5.03 billion, a PE ratio of 63.79, a price-to-earnings-growth ratio of 4.60 and a beta of 1.21. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $72.94. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter last year, the business earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, research analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Tuesday, September 23rd. Bruker’s dividend payout ratio (DPR) is 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.